3-(2-chloro-5-methylpyrimidin-4-yl)imidazo[1,2-a]pyridine | 1224708-18-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 英文名称: 3-(2-chloro-5-methylpyrimidin-4-yl)imidazo[1,2-a]pyridine
• CAS: 1224708-18-2
• 化学式: C₁₂H₉ClN₄
• 分子量: 244.683
• InChiKey: XOKZFBYADNSRBP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  43.1
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(2-chloro-5-methylpyrimidin-4-yl)imidazo[1,2-a]pyridine 、 4-(5-氨基吡啶-2-基)哌嗪-1-羧酸叔丁酯 在 sodium hydroxide 作用下， 以 乙二醇甲醚 为溶剂， 反应 2.0h， 以7%的产率得到4-(imidazo[1,2-a]pyridin-3-yl)-5-methyl-N-(6-(piperazin-1-yl)pyridin-3-yl)pyrimidin-2-amine
  参考文献：
  名称：

  [EN] DERIVATIVES OF 4-(IMIDAZO[1,2-A]PYRIDIN-3-YL)-N-(PYRIDIN-3-YL) PYRIMIDIN-2- AMINE FOR TREATING PROLIFERATIVE DISEASES AND CONDITIONS
  [FR] DÉRIVÉS DE 4-(IMIDAZO[1,2-A] PYRIDIN-3-YL)-N-(PYRIDIN-3-YL)PYRIMIDIN-2-AMINE POUR LE TRAITEMENT DE MALADIES ET D'AFFECTIONS PROLIFÉRATIVES

  摘要：

  一类新型的杂环芳基化合物，用于预防和/或治疗包括癌症在内的增殖性疾病和症状。这些化合物被认为能够通过抑制细胞增殖来抑制细胞蛋白激酶的活性，所选的蛋白激酶包括CDKs（如CDK2、CDK4、CDK6和/或CDK9）以及其他蛋白激酶，如FLT3及其突变体。这些化合物具有一般结构I：（I）

  公开号：

  WO2021072475A1
• 作为产物：
  描述：

  2-氨基吡啶 、 4-(2-Butoxyethenyl)-2-chloro-5-methylpyrimidine 在 N-溴代丁二酰亚胺(NBS) 、 水 作用下， 以 1,4-二氧六环 为溶剂， 反应 1.0h， 以63%的产率得到3-(2-chloro-5-methylpyrimidin-4-yl)imidazo[1,2-a]pyridine
  参考文献：
  名称：

  A versatile route to 3-(pyrimidin-4-yl)-imidazo[1,2-a]pyridines and 3-(pyrimidin-4-yl)-pyrazolo[1,5-a]pyridines

  摘要：

  A two-step synthesis of 3-(2-chloropyrimidin-4-yl)imidazo[1,2-a]pyridines is presented. The late stage elaboration of the imidazopyridine through a cyclocondensation allows a rapid access to a variety of substitution patterns. The intermediate enol ethers were obtained from inexpensive reagents in a ligand-free Heck coupling. This methodology has been extended to the formation of pyrazolo[1,5-a]pyridines via a formal 1,3-dipolar cycloaddition. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2010.07.024

文献信息

• [EN] DERIVATIVES OF 4-(IMIDAZO[L,2-A]PYRIDIN-3-YL)-N-(PYRIDINYL)PYRIMIDIN- 2-AMINE AS THERAPEUTIC AGENTS<br/>[FR] DÉRIVÉS DE 4-(IMIDAZO [L, 2-A] PYRIDINE-3-YL)-N-(PYRIDINYL) PYRIMIDINE-2-AMINE EN TANT QU'AGENTS THÉRAPEUTIQUES
  申请人：AUCENTRA THERAPEUTICS PTY LTD

  公开号：WO2021003517A1

  公开（公告）日：2021-01-14

  A novel class of heteroaryl compounds for use in the prevention and/or treatment of proliferative diseases and conditions including cancers. The compounds are considered to be capable of inhibiting cell proliferation by inhibiting the activity of FLT3 and its mutant forms and/or other protein kinases such as CDKs. The compounds have the general structure I:

  一类新型的杂环芳基化合物，用于预防和/或治疗包括癌症在内的增生性疾病和症状。这些化合物被认为能够通过抑制FLT3及其突变形式和/或其他蛋白激酶如CDK的活性来抑制细胞增殖。这些化合物具有一般结构I：
• NOVEL COMPOUNDS 515
  申请人：Ducray Richard

  公开号：US20100105655A1

  公开（公告）日：2010-04-29

  There is provided novel pyrimidine derivatives of formula (I) or pharmaceutically acceptable salts thereof, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

  提供了化学式（I）的新型嘧啶衍生物或其药用盐，以及它们的制备方法、含有它们的药物组合物以及它们在治疗中的应用。
• Derivatives of N-cycloalkyl/heterocycloalkyl-4-(imidazo[1,2-a]pyridine)pyrimidin-2-amine as therapeutic agents
  申请人：Aucentra Therapeutics Pty Ltd

  公开号：US11111245B2

  公开（公告）日：2021-09-07

  A novel class of inhibitors of protein kinases that are useful in the treatment of cell proliferative diseases and conditions, and especially those characterised by over-expression of one or more CDK enzyme and/or by one or more aberrant CDK activity, including certain cancers of lung, breast, brain, ovary, prostate, colorectal cancer and leukaemias. The inhibitors have the general structure (I).

  一类新型蛋白激酶抑制剂，可用于治疗细胞增殖性疾病和病症，特别是以一种或多种 CDK 酶过度表达和/或一种或多种 CDK 活性异常为特征的疾病和病症，包括某些肺癌、乳腺癌、脑癌、卵巢癌、前列腺癌、结直肠癌和白血病。这些抑制剂具有一般结构 (I)。
• DERIVATIVES OF 4-(IMIDAZO[L,2-A]PYRIDIN-3-YL)-N-(PYRIDINYL)PYRIMIDIN- 2-AMINE AS THERAPEUTIC AGENTS
  申请人：Aucentra Therapeutics Pty Ltd

  公开号：EP3997088A1

  公开（公告）日：2022-05-18
• DERIVATIVES OF N-CYCLOALKYL/HETEROCYCLOALKYL-4-(IMIDAZO[1,2-a]PYRIDINE)PYRIMIDIN-2-AMINE AS THERAPEUTIC AGENTS
  申请人：Aucentra Therapeutics Pty Ltd

  公开号：US20200231586A1

  公开（公告）日：2020-07-23

  A novel class of inhibitors of protein kinases that are useful in the treatment of cell proliferative diseases and conditions, and especially those characterised by over-expression of one or more CDK enzyme and/or by one or more aberrant CDK activity, including certain cancers of lung, breast, brain, ovary, prostate, colorectal cancer and leukaemias. The inhibitors have the general structure (I).